Ossium Health fetches $63m Series B

Ossium Health, a therapeutics company focused on using stem cell science to improve treatment for patients with blood and immune diseases, has closed $63 million in Series B funding.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this